Carisma Therapeutics Inc. (CARM)

NASDAQ: CARM · IEX Real-Time Price · USD
3.10
+0.01 (0.32%)
At close: Mar 31, 2023, 4:00 PM
3.12
+0.02 (0.65%)
After-hours: Mar 31, 2023, 7:59 PM EDT
0.32%
Market Cap 31.08M
Revenue (ttm) 40.00M
Net Income (ttm) -19.88M
Shares Out 10.03M
EPS (ttm) -2.00
PE Ratio n/a
Forward PE n/a
Dividend $0.36 (11.66%)
Ex-Dividend Date Mar 8, 2023
Volume 40,449
Open 3.09
Previous Close 3.09
Day's Range 3.05 - 3.20
52-Week Range 2.77 - 19.30
Beta n/a
Analysts n/a
Price Target 12.24 (+294.84%)
Earnings Date May 8, 2023

About CARM

Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutic... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 92
Stock Exchange NASDAQ
Ticker Symbol CARM
Full Company Profile

Financial Performance

In 2022, CARM's revenue was $40.00 million, an increase of 50.69% compared to the previous year's $26.54 million. Losses were -$19.88 million, 5817.9% more than in 2021.

Financial Statements

News

Sesen Bio Stockholders Approve Merger with Carisma Therapeutics

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today announced that its stockholders have voted to approve all proposals, including the pending merge...

1 month ago - Business Wire

Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN) today reported operating results for the fourth quarter and full year ended December 31, 2022, and provided a business update. Business Upda...

1 month ago - Business Wire

Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote “FOR” All Proposals to Approve Pending Merger With Carisma

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today announced that leading independent proxy advisory firm Glass, Lewis & Co. (“Glass Lewis”) recomm...

1 month ago - Business Wire

Leading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today announced that Institutional Shareholder Services (“ISS”) recommends that stockholders vote “FOR...

1 month ago - Business Wire

Sesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending Merger

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio, Inc. (Nasdaq: SESN) today announced that members of its management team will host a fireside chat with members of the Carisma Therapeutics Inc. (“Carisma”...

1 month ago - Business Wire

BML, One of Sesen Bio's Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today announced that BML Investment Partners, L.P. (“BML”), one of Sesen Bio's top stockholders, inten...

1 month ago - Business Wire

Sesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending Merger

CAMBRIDGE, Mass. & PHILADELPHIA--(BUSINESS WIRE)--Sesen Bio, Inc. (Nasdaq: SESN) and Carisma Therapeutics Inc. (Carisma), a privately-held, clinical stage biopharmaceutical company focused on discover...

1 month ago - Business Wire

Sesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics Merger

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio, Inc. (NASDAQ: SESN) today filed an investor presentation highlighting its value maximizing merger with Carisma Therapeutics Inc. (“Carisma”). The presen...

2 months ago - Business Wire

Sesen Bio Receives NASDAQ Delisting Notice

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”) today announced that it has received notice from the Listing Qualifications Department of The Nasdaq ...

2 months ago - Business Wire

Sesen Bio Reiterates Confidence that Pending Merger with Carisma is in Best Interests of Stockholders

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio, Inc. (Nasdaq: SESN) today issued the following statement reiterating the Company's confidence in, and commitment to, the pending merger with Carisma The...

2 months ago - Business Wire

Investor Group Issues Letter to the Boards of Sesen Bio and Carisma Rejecting Their Apparent Attempt to Purchase Merger Support

HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok (together with their affiliates, the “Investor Group” or “we”), who own approximately 8.4% of the outstanding common stock of Sesen Bio,...

2 months ago - Business Wire

Sesen Bio Files Definitive Proxy Statement and Mails Letter to Stockholders in Connection with Pending Merger with Carisma Therapeutics

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio, Inc. (Nasdaq: SESN) today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with the...

2 months ago - Business Wire

Investor Group Issues Letter to Sesen Bio's Board of Directors Regarding Intent to Vote AGAINST Proposed Carisma Merger

HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok (together with their affiliates, the “Investor Group” or “we”), who own approximately 8.4% of the outstanding common stock of Sesen Bio,...

3 months ago - Business Wire

Sesen Bio Reiterates Confidence in Pending Merger with Carisma Therapeutics

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio, Inc. (Nasdaq: SESN) today issued the following statement reiterating the Company's confidence in, and commitment to, the pending merger with Carisma The...

3 months ago - Business Wire

Investor Group Reiterates Intent to Vote AGAINST Sesen Bio's Value-Destructive Merger with Carisma

HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok (together with their affiliates, the “Investor Group” or “we”), who own approximately 8.4% of the outstanding common stock of Sesen Bio,...

3 months ago - Business Wire

Sesen Bio and Carisma Therapeutics Announce Substantial Increase to Expected Special Cash Dividend in Connection with Pending Merger

CAMBRIDGE, Mass. & PHILADELPHIA--(BUSINESS WIRE)--Sesen Bio, Inc. (Nasdaq: SESN) and Carisma Therapeutics Inc. (Carisma), a privately-held, clinical stage biopharmaceutical company focused on discov...

3 months ago - Business Wire

SHAREHOLDER ALERT: Weiss Law Investigates Sesen Bio, Inc.

NEW YORK , Dec. 13, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Sesen Bio, Inc. ("Sesen" or the "Compan...

3 months ago - PRNewsWire

SESEN BIO, INC. (SESN) Upgraded to Buy: What Does It Mean for the Stock?

SESEN BIO, INC. (SESN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

4 months ago - Zacks Investment Research

SESEN BIO, INC. (SESN) Flat As Market Gains: What You Should Know

In the latest trading session, SESEN BIO, INC. (SESN) closed at $0.50, marking no change from the previous day.

5 months ago - Zacks Investment Research

SESN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Sesen Bio, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Sesen Bio, Inc. (NASDAQ: SESN) and Carisma Therapeutics Inc. is fair to Sesen Bio share...

6 months ago - Business Wire

Sesen Bio and Carisma Therapeutics Announce Merger Agreement

CAMBRIDGE, Mass. & PHILADELPHIA--(BUSINESS WIRE)--Sesen Bio, Inc. (Nasdaq: SESN) and Carisma Therapeutics Inc. (Carisma), a privately held, clinical stage biopharmaceutical company focused on discover...

6 months ago - Business Wire

SESEN BIO, INC. (SESN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for SESEN BIO, INC. (SESN), indicating that the stock has found support.

7 months ago - Zacks Investment Research

Best Momentum Stocks to Buy for August 15th

BRT, ERJ, and SESN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 15, 2022.

Other symbols: BRTERJ
8 months ago - Zacks Investment Research

Sesen Bio Reports Second Quarter 2022 Financial Results and Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN) today reported operating results for the second quarter ended June 30, 2022. During the quarter, the Company paused clinical development of ...

8 months ago - Business Wire